Active	Status	Sponsor type	Region	Phase	Filter
3 Active 7 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Staehler, Michael
CARAT, NCT03374267: Registry Platform Urologic Cancer	Recruiting	N/A	1830	Europe	Routine care as per site standard.	iOMEDICO AG	Renal Cell Carcinoma, Urothelial Carcinoma	06/27	06/27
Casuscelli, Jozefina
ARASAFE, NCT05676203: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients	Recruiting	3	250	Europe	Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel	Jena University Hospital, Bayer	Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	07/25	01/27
Karpitschka, Martina
No trials found
Ingrisch, Michael
No trials found
Hellbach, Katharina
No trials found